CA
NZ
UK
AU
IND
US
…
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Curis Inc is a development-stage biopharmaceutical company focused on discovering and advancing targeted oncology therapies through internal programs and collaborative arrangements. Long-term growth may be driven by clinical progress across its pipeline, regulatory approvals or partner licensing and milestone or royalty payments, which could support value creation for investors seeking exposure to oncology R&D.
Material risks include high clinical and regulatory execution risk, likely continued financing needs that may dilute shareholders, and dependence on partner relationships and trial outcomes.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -7.58M | -43.39M | -47.41M | -56.67M | -45.44M |
| Net income | -7.58M | -43.39M | -47.41M | -60.32M | -50.64M |
| Selling general administrative | 14.05M | 16.79M | 18.65M | 19.65M | 17.30M |
| Gross profit | 9.40M | 10.81M | 10.02M | 9.90M | 10.12M |
| Reconciled depreciation | 0.17M | 0.20M | 0.28M | 0.23M | 0.16M |
| Ebit | -32.90M | -42.77M | -48.33M | -53.25M | -42.06M |
| Ebitda | -32.73M | -42.57M | -48.33M | -53.02M | -40.96M |
| Depreciation and amortization | 0.17M | 0.20M | 0.26M | 0.23M | 1.10M |
| Non operating income net other | - | - | - | -3.65M | -3.37M |
| Operating income | -32.90M | -44.54M | -48.33M | -53.02M | -42.06M |
| Other operating expenses | 42.34M | 55.45M | 58.35M | 63.18M | 52.71M |
| Interest expense | 2.19M | 0.61M | 2.02M | 4.77M | 4.47M |
| Interest income | 0.32M | 1.77M | 2.81M | 1.12M | 0.21M |
| Net interest income | -1.87M | 1.15M | -1.96M | -3.65M | -4.26M |
| Non recurring | - | - | - | 0.26M | 0.53M |
| Income tax expense | - | - | -0.26M | 3.65M | 5.20M |
| Total revenue | 9.44M | 10.91M | 10.02M | 10.16M | 10.65M |
| Total operating expenses | 42.34M | 55.35M | 58.35M | 62.92M | 52.18M |
| Cost of revenue | 0.04M | 0.10M | 0.23M | 0.26M | 0.53M |
| Total other income expense net | 25.32M | 1.15M | 0.92M | -3.65M | -3.37M |
| Net income from continuing ops | -7.58M | -43.39M | -47.03M | -56.67M | -45.44M |
| Net income applicable to common shares | - | - | - | -56.67M | -45.44M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 19.97M | 41.27M | 77.28M | 108.85M | 162.30M |
| Other current assets | 1.85M | 3.04M | 1.78M | 3.52M | 3.27M |
| Total liab | 14.50M | 47.26M | 57.61M | 62.30M | 71.59M |
| Total stockholder equity | 5.46M | -6.00M | 19.67M | 46.55M | 90.71M |
| Other current liab | - | 14.67M | 9.04M | 5.68M | 6.34M |
| Common stock | 0.13M | 0.09M | 0.06M | 0.97M | 0.92M |
| Capital stock | 0.13M | 0.09M | 0.06M | 0.97M | 0.92M |
| Retained earnings | -1247.38M | -1239.80M | -1196.41M | -1149.00M | -1092.33M |
| Other liab | - | - | - | 49.48M | 53.80M |
| Good will | 8.98M | 8.98M | 8.98M | 8.98M | 8.98M |
| Other assets | 2.35M | - | - | 2.66M | 0.73M |
| Cash | 5.06M | 20.00M | 26.68M | 19.66M | 40.01M |
| Total current liabilities | 14.08M | 19.03M | 13.52M | 12.81M | 17.80M |
| Net debt | -3.44M | -17.04M | -23.89M | -12.92M | -34.97M |
| Short term debt | 1.19M | 1.34M | 1.30M | 3.94M | 5.04M |
| Short long term debt total | 1.62M | 2.95M | 2.79M | 6.74M | 5.04M |
| Other stockholder equity | 1252.71M | 1233.72M | 1215.79M | 1194.77M | 1182.22M |
| Property plant equipment | - | - | - | 0.69M | 0.51M |
| Total current assets | 5.06M | 26.39M | 60.91M | 89.23M | 143.80M |
| Long term investments | - | - | - | 0.00M | 23.96M |
| Net tangible assets | - | - | - | 37.57M | 81.72M |
| Short term investments | - | 0.00M | 29.65M | 65.97M | 75.87M |
| Net receivables | 0.00M | 3.35M | 2.79M | 2.98M | 3.22M |
| Inventory | - | - | - | -2.89M | -2.54M |
| Accounts payable | 12.89M | 3.02M | 3.17M | 3.19M | 6.42M |
| Accumulated other comprehensive income | - | - | 0.23M | -0.19M | -0.11M |
| Common stock total equity | - | - | - | 0.97M | 0.92M |
| Retained earnings total equity | - | - | - | -1149.00M | -1092.33M |
| Non currrent assets other | -0.54M | 1.96M | 2.52M | 5.54M | 3.27M |
| Non current assets total | 12.55M | 14.88M | 16.37M | 19.61M | 18.50M |
| Capital lease obligations | 1.62M | 2.95M | 2.79M | 3.94M | 5.04M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | 29.44M | 26.73M | 33.44M | -47.90M |
| Change to liabilities | - | - | - | -3.88M | 4.96M |
| Total cashflows from investing activities | 2.50M | 29.44M | 37.79M | 33.02M | -47.90M |
| Total cash from financing activities | 9.77M | 3.44M | 7.58M | 0.87M | -4.17M |
| Change to operating activities | - | - | - | -3.18M | -3.78M |
| Net income | -7.58M | -43.39M | -47.41M | -56.67M | -45.44M |
| Change in cash | -14.94M | -6.68M | 6.93M | -20.45M | -89.69M |
| Begin period cash flow | 20.54M | 27.23M | 20.29M | 40.74M | 130.43M |
| End period cash flow | 5.61M | 20.54M | 27.23M | 20.29M | 40.74M |
| Total cash from operating activities | -27.20M | -39.56M | -38.43M | -54.34M | -37.62M |
| Issuance of capital stock | 15.35M | 12.02M | 13.74M | 5.59M | 0.00M |
| Depreciation | 0.17M | 0.19M | 0.26M | 0.23M | 0.16M |
| Other cashflows from investing activities | 2.50M | - | - | - | - |
| Change to account receivables | -1.03M | -0.56M | 0.18M | 0.25M | -0.18M |
| Sale purchase of stock | - | - | - | 5.84M | 0.30M |
| Other cashflows from financing activities | 9.77M | -8.59M | -6.54M | -4.73M | -4.47M |
| Change to netincome | - | - | - | 2.33M | 7.82M |
| Capital expenditures | 0.00M | 0.00M | 0.42M | 0.42M | 0.42M |
| Cash and cash equivalents changes | - | - | - | -20.45M | -89.69M |
| Change in working capital | 1.75M | -3.72M | 2.78M | -6.82M | 1.00M |
| Stock based compensation | 4.02M | 5.93M | 6.00M | 6.75M | 5.28M |
| Other non cash items | -25.56M | 1.43M | -0.06M | 2.17M | -0.03M |
| Free cash flow | -27.20M | -39.56M | -38.43M | -54.75M | -37.62M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CRIS Curis Inc |
0.03 6.68% |
0.40 | - | - | 2.54 | 4.49 | 2.23 | 0.56 |
| NVO Novo Nordisk A/S |
-0.46 1.18% |
38.67 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.54 0.68% |
521.03 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
8.43 1.04% |
816.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. James E. Dentzer | Pres, CEO & Director | 1967 |
| Dr. Robert E. Martell M.D., Ph.D. | Head of R&D | 1963 |
| Ms. Diantha Duvall CPA, M.B.A. | CFO, Treasurer, Assistant Sec., Principal Financial Officer & Principal Accounting Officer | 1972 |
| Mr. Mark W. Noel | VP of Technology Management & Intellectual Property | 1959 |
| Ms. Elif McDonald | VP of Investor Relations & Corp. Communications | NA |
| Dr. Reinhard Wilhelm von Roemeling M.D. | Sr. VP of Clinical Devel. | NA |
| Mr. James E. Dentzer | President, CEO, Secretary, Treasurer & Director | 1967 |
| Ms. Diantha Duvall C.P.A., M.B.A. | CFO and Principal Financial & Accounting Officer | 1972 |
| Mr. Mark W. Noel | Vice President of Technology Management & Intellectual Property | 1959 |
| Ms. Elif McDonald | VP of Investor Relations & Corporate Communications | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...